Pneumonia

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Retrieved on: 
Tuesday, January 2, 2024

Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.

Key Points: 
  • Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.
  • This Phase 2 study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • The Inventprise PCV includes 25 serotypes—expanding the potential to prevent several deadly and emerging serotypes not yet addressed by existing PCVs.
  • A Phase 2 study in older adults is also planned to take place in the second half of 2024.

HKTDC and Hang Seng Bank's InnoClub celebrate exceptional local entrepreneurs

Retrieved on: 
Friday, December 8, 2023

Mr Stephen Liang, Assistant Executive Director of HKTDC, said, "The HKTDC provides comprehensive year-round support to SMEs and start-ups, helping them transform and grow and seize arising opportunities.

Key Points: 
  • Mr Stephen Liang, Assistant Executive Director of HKTDC, said, "The HKTDC provides comprehensive year-round support to SMEs and start-ups, helping them transform and grow and seize arising opportunities.
  • InnoClub recognises the tremendous advances Hong Kong has been making in I&T and contributes to the sector's continued growth.
  • InnoClub, which we established in partnership with HKTDC, provides a unique platform to drive the growth of its members.
  • Dr Bin Ye, Founder of Decode Cure, said: "In InnoClub, there are a lot of companies in the early development stages.

The Inner Circle Acknowledges, Rocco Terrigno, MD as a Pinnacle Lifetime Member

Retrieved on: 
Friday, December 29, 2023

MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.

Key Points: 
  • MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.
  • Dr. Rocco Terrigno a renowned pulmonologist and critical care intensivist, is making a significant impact in the field of respiratory medicine.
  • Dr. Terrigno's expertise encompasses a wide range of respiratory conditions, including cough, interstitial lung disease/sarcoid, COPD/emphysema, asthma, sleep disorders, lung nodules, pleural disease, respiratory failure, and COVID-19 pneumonia.
  • Currently, Dr. Terrigno serves as a fellowship-trained pulmonologist and critical care intensivist in the Department of Critical Care Medicine at Cooper University Hospital in Camden, New Jersey.

EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

Retrieved on: 
Saturday, December 30, 2023

Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.

Key Points: 
  • Biotest announced this week that the first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated in the multinational phase III TRICOVID trial.
  • The TRICOVID trial was already enrolling hospitalized patients with COVID-19 who require supplemental oxygen due to the severity of their disease.
  • However, trimodulin is not only expected to be effective in treatment of COVID-19 patients.
  • This further expedites the development of trimodulin as potential new treatment option for a broad population of hospitalized patients with CAP”, emphasized Dr Thomas Häder, Head of Clinical Strategy and Development at Biotest.

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Retrieved on: 
Tuesday, December 26, 2023

No evidence of his lymphoma was found histologically, based on the patient’s initial autopsy report.

Key Points: 
  • No evidence of his lymphoma was found histologically, based on the patient’s initial autopsy report.
  • Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics, commented, "The safety of every patient who participates in our studies is of the utmost priority for us.
  • We believe these early disease response data indicate that ONCT-808 is a particularly potent autologous CAR T product with the potential to address significant unmet needs for patients with aggressive B-cell malignancies.
  • With this clear path forward, we plan to implement the protocol amendment as rapidly as possible."

Nonprofit BlinkNow Provides Aid for Jajarkot Earthquake Crisis in Nepal

Retrieved on: 
Wednesday, December 20, 2023

BlinkNow is celebrating this year of deepening roots and meaningful growth, which led to the opportunity to serve people in the surrounding region when disaster struck.

Key Points: 
  • BlinkNow is celebrating this year of deepening roots and meaningful growth, which led to the opportunity to serve people in the surrounding region when disaster struck.
  • Kopila Valley staff and volunteers traveled for hours through mountainous regions to deliver supplies to the hardest-hit areas of the earthquake.
  • This included clearing roads, geo-tagging distribution routes for others, and driving farther than other aid agencies may be able to reach.
  • The BlinkNow Foundation was founded in 2007 and provides an education and a loving, caring home for children without homes, impoverished and at-risk children.

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Retrieved on: 
Wednesday, December 20, 2023

Nes-Ziona, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all 120 patients in its Phase II trial of Allocetra™ in patients with sepsis.

Key Points: 
  • Nes-Ziona, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all 120 patients in its Phase II trial of Allocetra™ in patients with sepsis.
  • The Phase II trial is a placebo-controlled, randomized, dose-finding, multi-country, multi-center study, evaluating frozen-formulation Allocetra™ in addition to standard of care in patients with sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.
  • Sepsis is a life-threatening disease with no therapies approved by the U.S. Food and Drug Administration and a high unmet need.
  • “The completion of the enrollment in our Phase II trial of Allocetra™ in patients with sepsis is an important execution milestone for Enlivex, meeting our enrollment timeline” stated Einat Galamidi, Medical Vice President of Enlivex.

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat

Retrieved on: 
Wednesday, December 13, 2023

AUSTIN, TX & DURHAM, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.

Key Points: 
  • That patient remains disease free.” said Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck.
  • TP53m AML: In 11 evaluable patients with previously untreated TP53m AML, two patients achieved a CR.
  • Safety: Preliminary data suggest that SL-172154 has an acceptable safety and tolerability profile in combination with azacitidine.
  • To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website here .

Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical Trial to Treat Acute Respiratory Distress Syndrome (ARDS)

Retrieved on: 
Thursday, December 21, 2023

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).

Key Points: 
  • The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).
  • BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
  • Under this contract, the PPD clinical research business will implement a large Phase II clinical trial over three years.
  • The PPD clinical research business will support the clinical trial with its deep capabilities and expertise in end-to-end platform clinical trials, seamless biomarker testing, and critical care, drug depot and laboratory services.

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Retrieved on: 
Friday, December 15, 2023

Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.

Key Points: 
  • Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
  • Patients could have received up to three prior treatment regimens and were required to have measurable disease per RECIST v1.1.
  • Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients.
  • Adverse reactions that required dose reduction in ≥1% of patients were hypoxia (5%) and anemia (3.2%).